About CardioDex

Company Overview

CardioDex is developing a state the-art disposable solution for the closure of arterial access sites following cardiac catheterization procedures.

CardioDex offers the interventional cardiologists closure technologies that provide an extremely high success rate, under 2 minute deployment, and high cath-lab throughput, resulting in high cath-lab utilization and profit maximization. 

The Company was founded by one of the most renowned medical entrepreneurs in Israel, Dr. Shimon Eckhouse, a scientist who enjoys vast experience and international successes. Dr. Eckhouse was the founder, CEO and Chairman of ESC Lumenis (NASDAQ: LUME) a company that reached sales of more than USD 440 million and a market cap of over USD 1 billion.  

The Company has an ISO 9001:2000 ISO 9004:2000 and EN 13485:2003 approved manufacturing facility.

The company’s flagship product, the EpiClose^® Plus overcomes the limitations that cardiologists, cath-labs and patients are currently confronted with, in an unprecedented manner CardioDex’s products do not use any glue, collagen, suturing or other foreign materials that might promote a clinical reaction, and do not deposit any residual material in the patient’s body. In addition, the products do not require exchange of the introducer sheath, and permit re-access to the artery should a non-deployment occur.

The Company enjoys a rich intellectual property portfolio and a strong and concrete IP coverage for it’s as current and future technology applications.

CardioDex enjoys the support of a clinical advisory board that consists of distinguished and well-acclaimed physicians who have gained worldwide recognition in Interventional Cardiology, Cardiovascular Surgery and related research. The Scientific Advisory Board includes among others Prof. Charles Davidson and Dr. Maurice Buchbinder. The strong corroboration with this respected team of cardiologists is a solid indication of their belief in the company and its products.